| 摘要 |
A method of determining CCNE2 in a body fluid sample of patients at risk for solid tumor disease. A multi-marker panel is preferably used for detecting circulating tumor cells, comprising CCNE2, DKFZp762E1312, EMP2, MAL2, PPIC, SLC6A8 and GTF2IRD1, and optionally further comprising one or more markers from the group consisting of AGR2, FXYD3, S100A16, TFF1, mammaglobin A, FN, Epcam, tm4sf and rbpms. |
